Business
Investors in drugmaker Mesoblast sweat on crucial capital raising – Sydney Morning Herald
The stem cell giant says it needs cash from its existing partnerships to ‘continue as a going concern’.
The ability of the group to continue as a going concern and realise its assets and discharge its liabilities in the normal course of business are dependent on cash inflows from successfully completing the private placement, as well as from existing strategic and financing partnerships, the auditors report said.
Analysts at Bell Potter noted last month that Mesoblasts balance sheet could come under pressure in the 2022 financial year if there were any hiccups with agreements and payments from partners…
-
Noosa News23 hours agoChild dies in house fire, six people in hospital
-
General19 hours agoCan WA Labor deliver election promise of $150m vanadium battery for Kalgoorlie by 2029?
-
General15 hours agoLabor’s Josh Wilson narrowly wins federal seat of Fremantle from independent Kate Hulett
-
Noosa News12 hours agoAccused admits lying to police over death of flatmate in Hamilton, Brisbane